Randomized studies in follicular lymphoma patients using a combination of rituximab plus chemotherapy
| Treatment . | Patients within each FLIPI strata (% with low/intermediate/high risk, respectively) . | Median age, y . | Estimated % PFS in the experimental arm . | Median PFS, m . | Overall survival % . | ||
|---|---|---|---|---|---|---|---|
| Control arm . | Experimental arm . | Control arm . | Experimental arm . | ||||
| CVP versus R-CVP16,31 | 19/41/40 | 52 | 50 (at 3 years) | 15 | 34 | 77 (at 4 years) | 83* (at 4 years) |
| CHOP versus R-CHOP†17 | 14/41/45 | 55 | 80 (at 2 years) | 31 | not reached | 90 (at 2 years) | 95* (at 2 years) |
| MCP versus R-MCP‡18 | 7/37/56 | 59 | 71 (at 4 years) | 26 | not reached | 74 (at 4 years) | 87* (at 4 years) |
| CHVP+I versus R-CHVP+I | 19/35/46 | 61 | 53 (at 5 years) | 35 | not reached | 79 (at 5 years) | 84 (at 5 years) |
| Treatment . | Patients within each FLIPI strata (% with low/intermediate/high risk, respectively) . | Median age, y . | Estimated % PFS in the experimental arm . | Median PFS, m . | Overall survival % . | ||
|---|---|---|---|---|---|---|---|
| Control arm . | Experimental arm . | Control arm . | Experimental arm . | ||||
| CVP versus R-CVP16,31 | 19/41/40 | 52 | 50 (at 3 years) | 15 | 34 | 77 (at 4 years) | 83* (at 4 years) |
| CHOP versus R-CHOP†17 | 14/41/45 | 55 | 80 (at 2 years) | 31 | not reached | 90 (at 2 years) | 95* (at 2 years) |
| MCP versus R-MCP‡18 | 7/37/56 | 59 | 71 (at 4 years) | 26 | not reached | 74 (at 4 years) | 87* (at 4 years) |
| CHVP+I versus R-CHVP+I | 19/35/46 | 61 | 53 (at 5 years) | 35 | not reached | 79 (at 5 years) | 84 (at 5 years) |
CHOP indicates cyclophosphamide, doxorubicin, vincristine, and prednisone; R-CHOP, rituximab, cyclophosphamide, doxorubicin, vincristine, and prednisone; PFS, progression-free survival; ASCT, autologous stem cell transplantation; IFN, interferon; MCP, mitoxantrone, chlorambucil, prednisone; and R-MCP, rituximab, mitoxantrone, chlorambucil, prednisone.
P value for difference in overall survival significant.
CHOP or R-CHOP was followed by ASCT or IFN.
MCP and R-MCP were followed by IFN consolidation.
§CHVP combined with IFN: 12 chemotherapy courses in the control arm versus 6 in the rituximab-containing arm.